From the publishers of The New England Journal of Medicine
Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.
Some content may require paid access to the site. Subscribe or
purchase a seven-day site pass for the full text of
all our clinical perspectives on medical journal articles, guidelines, and news.
As reported at IAS 2011, the effect size was small but still worrisome.
Trial data presented at IAS 2011 demonstrate some virologic and immunologic benefit to starting antiretroviral therapy during acute HIV infection.
The efficacy of tenofovir + 3TC + nevirapine is questionable, according to a systematic review presented at IAS 2011.
In a small trial presented at IAS 2011, 75% of patients on this regimen achieved virologic suppression at 48 weeks, compared with 84% of those on tenofovir/FTC + boosted atazanavir.
Virologic failures are less common after the switch, according to data presented at IAS 2011.
In a phase II trial presented at IAS 2011, rates of virologic suppression were 79% in patients receiving lersivirine and 86% in those receiving efavirenz.
Data presented at IAS 2011 support using elvitegravir + a ritonavir-boosted protease inhibitor + a third active agent in HIV-infected patients who have virologic failure after receiving two or more antiretroviral drug classes.
In a 48-week analysis presented at IAS 2011, this once-daily integrase inhibitor was shown to be both safe and effective among treatment-naive patients.
Our physician-editors highlight the most clinically relevant findings from the meeting in Rome.
Use of ritonavir-boosted atazanavir and lopinavir/ritonavir emerged as risk factors in studies presented at IAS 2011.